Prothena assumed with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Charles Duncan assumed coverage of Prothena with an Overweight rating and raised his price target for the shares to $20 from $18. Prothena’s lead candidate prasinezumab for the treatment of Parkinson’s disease is a potential first-in-class anti-alpha-synuclein antibody, targeting an evidence-based mechanism of disease pathology, Duncan tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2873519
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.